8,283 Shares in Pfizer Inc. $PFE Purchased by Northside Capital Management LLC

Northside Capital Management LLC purchased a new position in Pfizer Inc. (NYSE:PFE) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 8,283 shares of the biopharmaceutical company’s stock, valued at approximately $201,000.

Other institutional investors also recently modified their holdings of the company. GKV Capital Management Co. Inc. bought a new position in shares of Pfizer in the 1st quarter worth about $27,000. North Capital Inc. bought a new stake in Pfizer during the 1st quarter valued at about $28,000. Bayforest Capital Ltd bought a new stake in Pfizer during the 1st quarter valued at about $28,000. Horizon Financial Services LLC bought a new stake in Pfizer during the 1st quarter valued at about $35,000. Finally, WPG Advisers LLC bought a new stake in Pfizer during the 1st quarter valued at about $35,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Performance

Shares of NYSE PFE opened at $24.07 on Thursday. The firm’s 50-day moving average price is $24.59 and its 200-day moving average price is $24.18. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The company has a market cap of $136.82 billion, a PE ratio of 12.80, a PEG ratio of 0.85 and a beta of 0.55. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $30.43.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm’s revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Wall Street Analysts Forecast Growth

PFE has been the subject of a number of analyst reports. Morgan Stanley raised their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 6th. Wall Street Zen upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Saturday, September 20th. Berenberg Bank reduced their price objective on shares of Pfizer from $28.00 to $25.00 and set a “hold” rating for the company in a research note on Thursday, May 29th. Citigroup raised their price target on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Finally, Bank of America raised their price target on shares of Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Pfizer has an average rating of “Hold” and an average price target of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.